(資料圖片)
湖南省腫瘤醫(yī)院消化泌尿內(nèi)一科主任
主任醫(yī)師，醫(yī)學(xué)博士，博士后
湖南省醫(yī)學(xué)會(huì)消化腫瘤內(nèi)科學(xué)組組長
湖南省抗癌協(xié)會(huì)腫瘤靶向治療專委會(huì)主任委員
湖南省抗癌協(xié)會(huì)大腸癌專委會(huì)副主任委員
湖南省抗癌協(xié)會(huì)家族遺傳性腫瘤專委會(huì)副主任委員
湖南省醫(yī)促會(huì)惡性腫瘤精準(zhǔn)與綜合診療專委會(huì)副主任委員
[2]L. Shen, D. Liu, N. Li,et al. Osemitamab in combination with capecitabine and oxaliplatin (CAPOX) as a first line treatment of advanced G/GEJ cancer: Updated data of cohort C from a phase I/IIa, multi-center study (TranStar102/TST001-1002). 2023 ESMO WCGIC. Abstract PD-7.[3]Z. Wainberg, Y. Kang, K. Lee, et al. Bemarituzumab for treatment of previously untreated advanced and/or metastatic gastric and gastroesophageal cancer (GC): Final analysis of a randomized phase 2 trial (FIGHT). 2023 ESMO WCGIC. Abstract SO-11.[4]T. Satoh, P. Barthélémy, L. Nogova, et al. Phase 2 Study of Futibatinib in Patients With Specific FGFR Aberrations: Activity in Patients With Gastric or Gastroesophageal Junction Cancer Harboring FGFR2 Amplification. 2023 ESMO WCGIC. Abstract SO-10.[5]Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010 Aug 28;376(9742):687-97.[6]Hofheinz R , Hegewischbecker S , Thusspatience P C , et al. HER-FLOT: Trastuzumab in combination with FLOT as perioperative treatment for patients with HER2-positive locally advanced esophagogastric adenocarcinoma: A phase II trial of the AIO Gastric Cancer Study Group.2014 ASCO. Abstract 4073.[7]Shitara K, Lordick F, Bang YJ, et al. Zolbetuximab + mFOLFOX6 as first-line (1L) treatment for patients (pts) with claudin-18.2+ (CLDN18.2+) / HER2? locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma: Primary results from phase 3 SPOTLIGHT study. 2023 ASCO GI. Abstract LBA292.[8]Xu Rh, Shitara K, Ajani JA, Zolbetuximab + CAPOX in 1L claudin-18.2+ (CLDN18.2+)/HER2? locally advanced (LA) or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma: Primary phase 3 results from GLOW. 2023 ASCO GI. Abstract 405736.[9]Kohei Shitara, Rui-Hua Xu, Diarmuid Martin Moran, et al. Global prevalence of CLDN18.2 in patients with locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma: Biomarker analysis of two zolbetuximab phase 3 studies (SPOTLIGHT and GLOW). 2023 ASCO. Abstract 4035.本材料由阿斯利康提供，僅供醫(yī)療衛(wèi)生專業(yè)人士進(jìn)行醫(yī)學(xué)科學(xué)交流，不用于推廣目的審批編號(hào)：CN-120160 過期日期：2024-2-9* 此文僅用于向醫(yī)學(xué)人士提供科學(xué)信息，不代表本平臺(tái)觀點(diǎn)
標(biāo)簽：
所刊載信息部分轉(zhuǎn)載自互聯(lián)網(wǎng)，并不代表本網(wǎng)贊同其觀點(diǎn)和對(duì)其真實(shí)性負(fù)責(zé)。郵箱：5855973@qq.com
聯(lián)系我們| 中國品牌網(wǎng) | 滬ICP備2022005074號(hào)-18 營業(yè)執(zhí)照 Copyright © 2018@. All Rights Reserved.
